A highly potent peptide analgesic that protects against ischemia-reperfusion-induced myocardial stunning.

We recently discovered an opioid peptide analgesic, 2',6'-dimethyltyrosine (Dmt)-D-Arg-Phe-Lys-NH(2) ([Dmt(1)]DALDA), that can protect against ischemia-induced myocardial stunning. In buffer-perfused hearts, 30-min global ischemia followed by reperfusion resulted in a significant increase in norepinephrine (NE) overflow immediately upon reperfusion and significant decline in contractile force (45%). Pretreatment with [Dmt(1)]DALDA before ischemia completely abolished myocardial stunning and significantly reduced NE overflow (68%). In contrast, pretreatment with morphine before ischemia only provided brief protection against myocardial stunning and no reduction in NE overflow. [Dmt(1)]DALDA inhibited [(3)H]NE uptake into cardiac synaptosomes in vitro (IC(50) = 3.9 microM), whereas morphine had no effect. Surprisingly, protection against myocardial stunning was apparent even when hearts were perfused with [Dmt(1)]DALDA only upon reperfusion, whereas reperfusion with morphine had no effect. Binding studies with [(3)H][Dmt(1)]DALDA revealed no high-affinity specific binding in cardiac membranes, suggesting that the cardioprotective actions of [Dmt(1)]DALDA are not mediated via opioid receptors. These findings suggest that [Dmt(1)]DALDA is a potent analgesic that may be useful for myocardial stunning resulting from cardiac interventions or myocardial ischemia.

[1]  A. Jessel,et al.  Development of the Na+/H+ Exchange Inhibitor Cariporide as a Cardioprotective Drug: From the Laboratory to the GUARDIAN Trial , 1999, Journal of Thrombosis and Thrombolysis.

[2]  A. Schömig,et al.  Nonexocytotic noradrenaline release and ventricular fibrillation in ischemic rat hearts , 1995, Naunyn-Schmiedeberg's Archives of Pharmacology.

[3]  H. Szeto,et al.  Profound Spinal Tolerance after Repeated Exposure to a Highly Selective μ-Opioid Peptide Agonist: Role of δ-Opioid Receptors , 2002 .

[4]  H. Szeto,et al.  Profound spinal tolerance after repeated exposure to a highly selective mu-opioid peptide agonist: role of delta-opioid receptors. , 2002, The Journal of pharmacology and experimental therapeutics.

[5]  R. Kloner,et al.  Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part 1. , 2001, Circulation.

[6]  H. Szeto,et al.  Resensitization of Blood Pressure Response to &mgr;-Opioid Peptide Agonists After Acute Desensitization , 2001, Anesthesia and analgesia.

[7]  K. Przyklenk Pharmacologic treatment of the stunned myocardium: the concepts and the challenges. , 2001, Coronary artery disease.

[8]  H. Szeto,et al.  In vivo pharmacokinetics of selective mu-opioid peptide agonists. , 2001, The Journal of pharmacology and experimental therapeutics.

[9]  N. Shimoyama,et al.  Antinociceptive and respiratory effects of intrathecal H-Tyr-D-Arg-Phe-Lys-NH2 (DALDA) and [Dmt1] DALDA. , 2001, The Journal of pharmacology and experimental therapeutics.

[10]  R. Kloner,et al.  Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part 2. , 2001, Circulation.

[11]  D. Allen,et al.  Activity of the Na(+)/H(+) exchanger is critical to reperfusion damage and preconditioning in the isolated rat heart. , 2000, Cardiovascular research.

[12]  P. Schiller,et al.  Synthesis and in vitro opioid activity profiles of DALDA analogues. , 2000, European journal of medicinal chemistry.

[13]  J. Clapp,et al.  A peripheral site of action for the attenuation of baroflex-mediated bradycardia by intravenous mu-opioid agonists. , 2000, Journal of cardiovascular pharmacology.

[14]  D. Warltier,et al.  Mechanisms of postischemic contractile dysfunction. , 1999, The Annals of thoracic surgery.

[15]  D. Allen,et al.  Changes in intracellular Na+ and pH in rat heart during ischemia: role of Na+/H+ exchanger. , 1999, The American journal of physiology.

[16]  J. Clapp,et al.  Respiratory depression after intravenous administration of δ-selective opioid peptide analogs , 1999, Peptides.

[17]  J. Clapp,et al.  Respiratory depression after intravenous administration of delta-selective opioid peptide analogs. , 1999, Peptides.

[18]  A. Hsu,et al.  TAN-67, a δ1-opioid receptor agonist, reduces infarct size via activation of Gi/o proteins and KATP channels. , 1998, American journal of physiology. Heart and circulatory physiology.

[19]  A. Hsu,et al.  Ischemic preconditioning and morphine-induced cardioprotection involve the delta (delta)-opioid receptor in the intact rat heart. , 1997, Journal of molecular and cellular cardiology.

[20]  C. Wu,et al.  The mode of action of several opioids on cardiac muscle , 1997, Experimental physiology.

[21]  Z. Vogel,et al.  Distinct Components of Morphine Effects on Cardiac Myocytes are Mediated by the κ and δ Opioid Receptors , 1997 .

[22]  A. Hsu,et al.  Morphine mimics the cardioprotective effect of ischemic preconditioning via a glibenclamide-sensitive mechanism in the rat heart. , 1996, Circulation research.

[23]  ReuvenZimlichman,et al.  Expression of Opioid Receptors During Heart Ontogeny in Normotensive and Hypertensive Rats , 1996 .

[24]  H. Lander,et al.  Activation of histamine H3-receptors inhibits carrier-mediated norepinephrine release during protracted myocardial ischemia. Comparison with adenosine A1-receptors and alpha2-adrenoceptors. , 1996, Circulation research.

[25]  G. Wittert,et al.  Tissue distribution of opioid receptor gene expression in the rat. , 1996, Biochemical and biophysical research communications.

[26]  F. Llobell,et al.  Characterization of the opioid receptor subtypes mediating the negative inotropic effects of DAMGO, DPDPE and U-50,488H in isolated human right atria strips , 1995, Neuropeptides.

[27]  G. Gross,et al.  Evidence for involvement of opioid receptors in ischemic preconditioning in rat hearts. , 1995, The American journal of physiology.

[28]  R. Levi,et al.  Unmasking of activated histamine H3-receptors in myocardial ischemia: their role as regulators of exocytotic norepinephrine release. , 1994, The Journal of pharmacology and experimental therapeutics.

[29]  M. Laorden,et al.  Effects of μ-, δ- and κ-agonists on isolated right atria of the rat , 1994, Neuropeptides.

[30]  E. Topol,et al.  Recombinant human superoxide dismutase (h-SOD) fails to improve recovery of ventricular function in patients undergoing coronary angioplasty for acute myocardial infarction. , 1994, Circulation.

[31]  J. Roberts,et al.  Characterization of norepinephrine accumulation by a crude synaptosomal-mitochondrial fraction isolated from rat heart. , 1991, Life sciences.

[32]  A. Schömig,et al.  Catecholamines in myocardial ischemia. Systemic and cardiac release. , 1990, Circulation.

[33]  C. Caldarera,et al.  Opioid receptors in rat cardiac sarcolemma: effect of phenylephrine and isoproterenol. , 1989, Biochimica et biophysica acta.

[34]  L. Opie Reperfusion injury and its pharmacologic modification. , 1989, Circulation.

[35]  T. Vargish,et al.  Delta and Mu receptor agonists correlate with greater depression of cardiac function than morphine sulfate in perfused rat hearts. , 1989, Circulatory shock.

[36]  M. Lazdunski,et al.  The sodium/hydrogen exchange system in cardiac cells: its biochemical and pharmacological properties and its role in regulating internal concentrations of sodium and internal pH. , 1985, Journal of molecular and cellular cardiology.

[37]  E. Braunwald,et al.  The Stunned Myocardium: Prolonged, Postischemic Ventricular Dysfunction , 1982, Circulation.

[38]  V. Erspamer,et al.  Amino acid composition and sequence of dermorphin, a novel opiate-like peptide from the skin of Phyllomedusa sauvagei. , 2009, International journal of peptide and protein research.

[39]  H. Oldham,et al.  Effects of morphine on ventricular function and myocardial contractile force. , 1966, The American journal of physiology.